Linked Life Data

48887BiochemicalReaction1809

Source:http://www.reactome.org/biopax/48887BiochemicalReaction1809

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
biopax3:comment
8p11 myeloproliferative syndrome (EMS) is a myeloproliferative disorder that rapidly progresses to acute myeloid leukemia if not treated (reviewed in Jackson, 2010, Knights and Cook, 2010). A characteristic feature of EMS is the presence of fusion proteins that contain the kinase domain of FGFR1 and the oligomerization domain of an unrelated protein. This is believed to promote the ligand independent dimerization and activation of the kinase domain. To date, there are 11 identified partners that form fusion proteins with FGFR1 in EMS: ZMYM2 (Xiao, 1998; Popovici, 1998; Reiter, 1998; Ollendorff, 1999; Xiao, 2000), FGFR1OP1 (Popovici, 1999), CNTRL (Guasch, 2000), BCR (Demiroglu, 2001), FGFR1OP2 (Grand, 2004), TRIM24 (Belloni, 2005), CUX1 (Wasag, 2011), MYO18A (Walz, 2005), CPSF6 (Hidalgo-Curtis, 2008), HERV-K (Guasch, 2003) and LRRFIP1 (Soler, 2009)., Authored: Rothfels, K, 2012-02-09, Edited: Rothfels, K, 2012-05-16, Reviewed: Ezzat, S, 2012-05-15
biopax3:xref
biopax3:dataSource
biopax3:displayName
Dimerization of FGFR1 fusion proteins
biopax3:left
biopax3:participantStoichio...
biopax3:right